Table 2.
Percentages of cancer stem cells
| Stem cell % | Cell line | Conditions | Reference |
|---|---|---|---|
| 20% | SUM147 | control | [83] |
| 10% | SUM147 | treatment | [83] |
| 1–15% | MDA-MB-231 | [84] | |
| 1% | MDA-MB-231 | ALDH1 | [85] |
| 12% | MDA-MB-231 | Paclitaxel | " |
| 1–13% | SUM159 | with/− Paclitaxel | " |
| 6–24% | SUM149 | " | [86] |
| 8–34% | SUM159 | " | " |
| 0.2%–12% | tumors | ALDH1 | [87] |
| 3.10% | MDA-MB-231 | [88] | |
| 2.70% | MDA-MB-435 | " | |
| ~0.5% | SUM225 | CD44+/CD24−/ESA+ | [89] |
| ~2.5% | SUM149 | CD44+/CD24−/ESA+ | " |
| ~1.75% | SUM159 | CD44+/CD24−/ESA+ | " |
| ~2.5% | SUM1315 | CD44+/CD24−/ESA+ | " |
| ~2% | MDA-MB-231 | CD44+/CD24−/ESA+ | " |
| 9–20% | MDA-MB-231 | CD44+/CD24 | Our data |